Preventing outbreaks of foodborne pathogenic bacteria in edible sprouts via novel resistance-conferring seed treatments

通过新型抗性种子处理方法预防食用芽菜中食源性致病菌的爆发

基本信息

批准号：
10589851
负责人：
Murli Manohar
金额：
$ 99.13万
依托单位：
ASCRIBE BIOSCIENCE INC.
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-04-01 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10589851
关键词：
Address Affect Alfalfa Appearance Bacteria Bacterial Counts Biological Sciences Calcium Cessation of life Clover Consumption Development Disease Disease Outbreaks Dose Effectiveness Enteral Escherichia coli O157:H7 Food Safety Formulation Germination Growth Harvest Health Hazards Hospitalization Human Hypochlorite Incidence Industry Industry Standard Infection Infiltration Link Measures Methodology Methods Microbial Biofilms Nutrient Phase Plants Powder dose form Process Production Proliferating Public Health Recommendation Research Resistance Risk Role Safety Sales Salmonella Smell Perception Source System Taste Perception Technology Testing Time Tissues Toxic effect Toxicology Treatment Efficacy antimicrobial commercialization compare effectiveness defense response efficacy testing enteric pathogen experience foodborne foodborne illness foodborne outbreak hazard high risk human pathogen improved innovation large scale production microbial microbiome mung bean new technology novel pathogen pathogenic bacteria prevent prevent outbreaks scale up standard care treatment duration treatment effect

项目摘要

Abstract Ascribe Bioscience is developing a novel technology to prevent foodborne outbreaks caused by the consumption of edible sprouts. Sprouts are highly vulnerable to infection with human enteric bacterial pathogens at the seed stage. These pathogens then grow exponentially in the warm and humid conditions used for sprouting. Even low initial bacterial counts on seeds can result in unsafe microbial loads by the end of sprout production and processing. Moreover, the internalization of contaminating bacteria into seed tissues contaminates the sprout tissues from inside, rendering the application of antimicrobials largely ineffective. Sprouts have emerged as a significant source of foodborne illness and have become a public health hazard. Between 1996 and 2017, the U.S. experienced 58 foodborne illness outbreaks associated with sprouts, encompassing at least 1,953 illnesses, 212 hospitalizations, and 5 deaths. According to the FDA, no single treatment so far has been shown to eliminate pathogens on seeds or sprouts that cause foodborne illness. Ascribe Bioscience will use a natural, microbiome-derived molecule that activates and/or prime plant defenses at the seed stage, thereby conferring to sprouts an enhanced resistance against contamination by disease-causing bacterial pathogens. Ascribe's proposed treatment technology has the potential to dramatically improve the safety of edible sprouts by addressing both external and internal bacterial contamination. In Phase I, Ascribe has established the feasibility of the technology for the prevention of outbreaks related to human consumption of sprouts by demonstrating that treatment with our molecule can prevent Salmonella growth during the sprouting process in alfalfa. In Phase II, we will finalize the sprout seed treatment formulation and expand testing to a broader spectrum of sprout-pathogen systems. To support commercialization, we will perform toxicity and residue testing for regulatory approval, and refine synthesis methodologies to enable large-scale production of the active ingredient. The specific aims of this Phase II project are 1) Refine treatment formulation, including optimized formulation development, determination of the minimum effective dose and treatment duration, comparison of the effectiveness of the formulation versus the sprout industry-standard treatments, and measuring the effects of the formulation on germination, growth and sprout quality; 2) Test the efficacy of treatments against other illness-causing pathogens on a variety of sprout types, and evaluate it's role in altering bacterial abilities to form biofilm; 3) Demonstrate safety via toxicology studies and residue testing to support EPA approval; 4) Develop methods to scale the synthesis of active ingredient to pilot scale, and 5) Investigate the ability of the molecule to provide post-harvest protection to leafy greens. The proposed research is expected to yield commercial products that will prevent or dramatically reduce the incidence of sprout-related foodborne outbreaks.

抽象的 Ascribe Bioscience 正在开发一种新技术来预防食源性疫情消费食用豆芽。豆芽非常容易受到人类肠道细菌的感染种子阶段的病原体。这些病原体在温暖潮湿的条件下呈指数增长为了发芽。即使种子上的初始细菌计数较低，也可能导致发芽结束时微生物负荷不安全生产加工。此外，污染细菌内化到种子组织中从内部污染芽组织，使得抗菌剂的使用基本上无效。豆芽已成为食源性疾病的重要来源，并已成为公共卫生危害。 1996 年至 2017 年间，美国爆发了 58 起与豆芽相关的食源性疾病疫情，包括至少 1,953 例疾病、212 例住院治疗和 5 例死亡。据 FDA 称，没有任何单一迄今为止的治疗已被证明可以消除种子或豆芽上引起食源性疾病的病原体疾病。 Ascribe Bioscience 将使用一种天然的微生物衍生分子来激活和/或启动植物种子阶段的防御，从而赋予芽苗以增强的抵抗力引起疾病的细菌病原体。 Ascribe 提出的治疗技术有潜力通过解决外部和内部细菌问题，显着提高食用豆芽的安全性污染。在第一阶段，Ascribe 已经确定了该技术预防疫情爆发的可行性通过证明用我们的分子进行处理可以预防与人类食用豆芽有关苜蓿发芽过程中沙门氏菌的生长。在第二阶段，我们将完成芽苗种子的处理制定并将测试扩展到更广泛的芽孢病原体系统。支持商业化后，我们将进行毒性和残留测试以供监管部门批准，并完善合成能够大规模生产活性成分的方法。二期工程的具体目标 1) 完善处理配方，包括优化配方开发、确定最小处理配方有效剂量和治疗持续时间，制剂与芽苗效果的比较行业标准处理，并测量配方对发芽、生长和发芽的影响质量; 2) 测试针对多种芽苗类型的其他致病病原体的治疗效果，并评估它在改变细菌形成生物膜的能力方面的作用； 3) 通过毒理学研究证明安全性和残留测试以支持 EPA 批准； 4) 开发扩大活性成分合成规模的方法中试规模，以及 5) 研究分子为绿叶蔬菜提供收获后保护的能力。这拟议的研究预计将产生商业产品，从而防止或显着减少与芽苗相关的食源性疫情的发生率。